Table of Contents

General Procedures S2
Compound Synthesis and Characterization Data S3
MB-COMT inhibition assay S15 S-COMT inhibition assay S18 Table S1 , S-COMT potency data S21 Step 1: preparation of 5-benzyloxy-2-(hydroxymethyl)pyran-4-one (11a)
To a solution of kojic acid (10) (5.00 g, 35.2 mmol) and sodium hydroxide (1.55 g, 38.7 mmol) in methanol (70 mL) and water (7 mL) was added benzyl chloride (4.70 mL, 40.5 mmol) dropwise over 10 min. The resulting mixture was stirred at reflux for 2 h, then overnight at room temperature. After the solvent volume was reduced roughly in half in vacuo, water was added and the mixture extracted with EtOAc (2 x 200 mL). The EtOAc layers were combined, washed with water (3 x 100 mL), brine (50 mL), dried over MgSO4 and filtered. As the solvent was being removed in vacuo, a crystalline solid began to form. This material was collected by filtration, washed with EtOAc and air-dried to give 5-benzyloxy-2- Step 1 H-NMR (400 MHz, DMSO-d6) δ 7.54 (s, 1 H) 7.30 -7.44 (m, 5 H) 6.22 (s, 1 H) 5.00 (s, 2 H) 4.39 (s, 2 H) 3.84 (t, J = 6.19 Hz, 2 H) 2.80 (t, J = 6.06 Hz, 2 H)
2: preparation of 1-(2-aminoethyl)-5-benzyloxy-2-(hydroxymethyl)pyridin-4-one (12a)
Step 3: preparation of 7-benzyloxy-3,4-dihydropyrido[1,2-a]pyrazin-8-one (13a) N N O O 1-(2-aminoethyl)-5-benzyloxy-2-(hydroxymethyl)pyridin-4-one (12a) (49 g, 179 mmol) was dissolved in CHCl3 (400 mL) and MnO2 (78 g, 893 mmol) was added to the mixture which was heated overnight at 60 °C. The reaction mixture was filtered and the residue was concentrated to yield 7-benzyloxy-3,4-dihydropyrido[1,2-a]pyrazin-8-one (13a), which was used in the next step without further purification. MS,
Step 4: preparation of 7-benzyloxy-1,2,3,4-tetrahydropyrido[1,2-a] 
7-benzyloxy-3,4-dihydropyrido[1,2-a]pyrazin-8-one (13a) (46.4 g, 182 mmol) was dissolved in MeOH (500 mL). NaBH4 (20.71 g, 547 mmol) was added portionwise to the mixture and the mixture was stirred over 48 h at room temperature. The reaction mixture was then concentrated to give a residue (10 g) that was purified by chromatography (SiO2, DCM:MeOH:NH3 (7 N) (90:9:1) to yield 7-benzyloxy-1,2,3,4- Step 1: preparation of 2-(hydroxymethyl) -5-((4-methoxybenzyl) 
To a suspension of kojic acid (10) (25.4 g, 179 mmol) in anhydrous DMF (450 mL) was added potassium carbonate (29.6 g, 214 mmol) and alpha-chloro-4-methoxytoluene (30.8 g, 197 mmol, 26.7 mL) and the resulting suspension was stirred at 80ºC for 4 h. The reaction mixture was evaporated in vacuo (oil pump, high vacuum) and water (500 mL) was added. The resulting suspension was stirred for 30 minutes. The solids were filtered off and dried under air current for 30 minutes, then triturated from heptane:diethyl ether (1:1, 300 mL) and dried in a vacuum oven (40ºC) overnight to yield 38.44 g of 2-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)-4H-pyran-4-one (11a) as a brown solid, which was used in the next step without any further purification.
Step 2: preparation of 1-(2-aminoethyl)-2-(hydroxymethyl)-5-((4-methoxybenzyl) 
Ethylenediamine (38.2 g, 635 mmol, 42.9 mL) was added to a suspension of 2-hydroxymethyl)-5-((4-methoxybenzyl)oxy)-4H-pyran-4-one (11b) (33.3 g, 127 mmol) in Ethanol (400 mL). The reaction mixture was stirred for 4 h at 90°C and then stirred overnight at room temperature. The reaction mixture was concentrated to yield 1-(2-aminoethyl)-2-(hydroxymethyl)-5-((4-methoxybenzyl)oxy)pyridin-4(1H)-one (12b) (50.3 g) as a brown viscous oil which was used in the next step without any further purification. MS,
Step 3: Preparation of 7- ((4-methoxybenzyl) (38.6 g, 127 mmol) was dissolved in chloroform (400 mL) and stirred for a few minutes. MnO2 (55.1 g, 634 mmol) was added to the mixture was stirred at 60 °C overnight. The reaction mixture was filtered and the residue was Step 4: preparation of 7- [(4-methoxyphenyl) 
To a cooled (ice bath) solution of 7-[(4-methoxyphenyl)methoxy]-3,4-dihydropyrido[1,2-a]pyrazin-8-one (13b) (5.0 g, 17.59 mmol) in MeOH (100 mL) was added NaBH4 (672 mg, 1 eq.) and the resulting mixture was stirred at rt for 14 h. The reaction mixture was filtered on a bed of Celite/silica gel/Celite and rinsed with MeOH (3 x 10 mL). The solvent was evaporated to give a pale yellow solid (6.1 g). This solid was then dissolved in a DCM/MeOH (9:1). The mixture was then washed with brine. The organic layers were dried on MgSO4 and concentrated under vacuum to yield 7- [(4-methoxyphenyl) and sodium triacetoxyborohydride (388 mg, 1.83 mmol). The resulting mixture was stirred at room temperature for 18 h. The contents were treated with 1 N NaOH, added 10% Na2CO3 and extracted with CHCl3 (3x). The organic layers were combined, dried over Na2SO4, filtered and the solvent removed in vacuo to give a residue which was purified by automated normal-phase chromatography (0-30% Step 2 
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2-(2-ethylbutyl)-7-hydroxy-1,2,3,4-tetrahydro-8H-pyrido[1,2-a]pyrazin-8-one (18)
S12
N N O HO
Method B
0.6 mL of THF, 0.3 mL of EtOH and 0.1 mL of HOAc were added to 7-benzyloxy-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin-8-one (14a, 19.2 mg, 0.075 mmol). 2-ethylbutryaldehyde (11.3 mg, 13.8 µL, 1.5 eq.) followed by Si-BH3CN (Silicycle, 250 mg, 0.223 mmol, 3 eq.) were added. The resulting reaction mixture was stirred overnight at room temperature. The mixture was filtered, evaporated. The residue was then dissolved in CH3CN (2 mL) and purified by reverse phase preparative chromatography.
An aq. solution of HCl (1 mL, 6 N) was added to the purified and evaporated fractions and the mixture was heated at 100°C for 1.5 h. The solvent was evaporated under vacuum. The residue was dissolved in CH3CN / H2O 75 : 25 (2 mL) and the solvents evaporated under vacuum to yield 2-(2-ethylbutyl)-7- Step 2 To a suspension of 2-(benzenesulfonyl)-7-[(4-methoxyphenyl)methoxy]-3,4-dihydro-1H-pyrido[1,2-a]pyrazin-8-one (61.7 mg, 0.14 mmol) in Ethanol (5 mL) was added 6 M HCl (0.48 mL, 2.89 mmol). The resulting mixture was stirred at 80 °C for 2 h. After cooling, the solvent was removed in vacuo and the residue triturated with Et2O (3x). 
ADME assays
Kinetic solubility, hepatocyte stability, and MDCK Pgp efflux assays were performed at Sundia (http://www.sundia.com/site/discovery_dmpk_details). 
MB-COMT inhibition assay
MB-COMT enzyme purification:
MB-COMT was expressed in HEK293 cells using a pCDNA3.1 vector system and 293 Fectin.
Cells (300 mL) at 83% viability were pelleted (15,000 g, 4 °C, 5 min) and resuspended once in phosphate-buffered saline (PBS) and then in membrane buffer (15 mM Tris, pH 7.5, 1 mM EGTA, 0.3 mM EDTA, 2 mM MgCl2, PIC cocktail [Roche, Indianapolis, IN, ref. 04693159001]). The samples were then homogenized and frozen and defrosted twice in liquid nitrogen. DNase (Sigma-Aldrich, St. Louis, MO, cat no. D4527) was then added (5 µL per mL) and incubated for 10 min at room temperature. The samples were then centrifuged at 40,000 g at 4 °C for 25 min. The supernatant was discarded, and the pellet was resuspended in Tris-sucrose buffer (20 mM Tris, pH 7.4, 250 mM sucrose) and homogenized again. The resulting solution was aliquoted and stored at −80 °C until use. Although the lysate does undergo centrifugation steps, the enzyme concentrations stated herein refer to total protein contained in the extract.
Assay Procedure:
An HTRF kit purchased from CisBio was used: EPIgeneous methyltransferase assay, 10,000 tests, cat. 62SAHPEH. Assay reagents were kept frozen at −80 °C, thawed, and used immediately. Stock solutions were made and dispensed into single-use aliquots. No stability information is available longer than 1 day after freeze-thaw. 
Standard curves:
A standard curve was run on every plate. Using the HTRF ratio (665 nM/620 nM × 10 4 ), a standard curve is determined according to the manufacturer's instructions using a mixture of SAM and SAH, with the final concentration of SAM being equivalent to that used in the enzyme reaction mixture.
Determination of Inhibition:
Tolcapone is known to be a potent inhibitor of COMT and, as such, was used as a benchmark for assay performance. The assays were run under substrate Km,app conditions; the compound was (1 mL) were collected. The final destination buffer was 100 mM potassium phosphate, 1 mM DTT, 5 mM MgCl2, 20% glycerol at pH 7.2.
Compound Dilution:
All compounds were diluted to a final concentration of 1.5% DMSO from 10 mM stocks in two steps. Stock (7.5 μL) was diluted serially into 15 μL of DMSO. Then 4.5 μL of the previous was diluted into 55.5 μL of COMT assay buffer (50 mM Tris, 5-10 mM MgCl2, 2.5 mM DTT, pH 6.9). Then 1 μL of that was then deposited into a Corning low volume 384-well white flatbottom polystyrene NBS microplate in triplicate.
For 0 and 100% inhibition controls, DMSO and tolcapone (synthesized in house) were added to each assay plate. DMSO was added to 12 wells on the plate in a final concentration of 1.5%, and tolcapone was added to 12 wells on the plate with a final concentration of 10 μM.
Tolcapone was diluted to 666.6 μM and then diluted in two steps according to the procedure of the compounds above. DMSO (MilliporeSigma, St. Louis, MO) was also diluted according to the same scheme.
Enzyme Reaction:
COMT activity was measured using the MTase Glo methyltransferase assay (Promega, All reactions contained 20 μM high purity S-adenosyl methionine (SAM, CisBio, Bedford, MA) in COMT assay buffer (50 mM Tris, 5-10 mM MgCl2, 2.5 mM DTT, pH 6.9). For MB-COMT,
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the catechol substrate was 7 μM norepinephrine (MilliporeSigma, St. Louis, MO) and for S-COMT the substrate was 10 μM 7,8-dihydroxy-4-methylcoumarin(32) (MilliporeSigma, St.
Louis, MO).
Reactions were performed in a 37 °C incubator for 1 h. The plate was removed from the incubator and allowed to cool to room temperature for 15 min. MTase reagent A (Promega, Madison, WI) was first diluted 1:5 into RO water, and 1 μL was then added to the well. The plate was spun down, shaken, and allowed to incubate for 30 min at room temperature avoiding light.
Then 5 μL of MTase reagent B (Promega, Madison, WI) were added to all of the wells. The plate was spun down, shaken, and allowed to incubate for 30 min at room temperature avoiding light.
Luminescence was detected with a Tecan Infinite M100 Pro plate reader.
Standard Curve:
A standard curve was run on every plate. The amount of S-adenosyl homocysteine (SAH, CisBio, Bedford, MA) produced was determined using a standard curve and a linear backcalculation method. The standard curve comprised of varying concentrations of SAH from 500 nM down to 0 nM while maintaining a final SAM/SAH concentration of 50 μM. To correct for background levels present in the enzymatic lysate (MB-COMT), enzyme at assay concentration was added to the standard curve as well.
Determination of Inhibition:
Percentage inhibition was calculated by using 10 μM tolcapone value as 100% inhibition value and the DMSO control as the 0% inhibition value. The dose response curves were constrained at 0% inhibition while keeping the percentage inhibition of the highest compound concentration floating. IC50 was determined by nonlinear regressions and curve fitting using a four-parameter
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fit with a variable slope in the Dotmatics studies program. Potency data presented is an average of three separate experiments in which each data point was run in triplicate. All data are the mean values of at least three independent measurements.
